Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, has entered into a non-exclusive License and Supply Agreement with TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services. The aim of this agreement is to increase access to CleanCap mRNA capping technologies as demand for mRNA continues to rise.
Under the terms of the agreement, TriLink will provide Lonza with its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs. These will be used in Lonza’s global mRNA development and manufacturing services, spanning from pre-clinical studies to Phase III programs.
CleanCap technology offers a streamlined solution with over 95% capping efficiency, simplifying mRNA production processes in comparison to traditional capping methods. This advancement has the potential to accelerate programs from discovery to clinical trials by enhancing mRNA function, optimizing manufacturing processes, and maximizing capped material yield.
Drew Burch, President of Nucleic Acid Production at TriLink expressed his excitement about the partnership stating that “CleanCap technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield.” The collaboration with Lonza is expected to further support the advancement of mRNA technologies.
TriLink first introduced its CleanCap capping technology in 2017 which is now widely used in the production of approved mRNA and saRNA vaccines. In May 2023 TriLink launched its latest CleanCap analogue CleanCap M6 which demonstrated significant increase in mRNA expression compared to enzymatic capping methods. This innovative technology continues to drive advancements in